Product description

Name: Anti-CD11b (Integrin aM) [ICRF44]

Alternate name: Integrin Subunit Alpha M; Cell Surface Glycoprotein MAC-1 Subunit Alpha; Complement Component 3 Receptor 3 Subunit; CD11 Antigen-Like Family Member B; Leukocyte Adhesion Receptor MO1; CR-3 Alpha Chain; CD11B; CR3A; Macrophage Antigen Alpha Polypeptide); Neutrophil Adherence Receptor Alpha-M Subunit 3; Macrophage Antigen Alpha Polypeptide 3; Neutrophil Adherence Receptor 4; Antigen CD11b (P17) 3; CD11b Antigen; MAC-1; MAC1A; SLEB6; MO1A

Species Reactivity: Human; Primate

Host Species: Mouse

Strain: BALB/c

Clonality: Monoclonal

Clone: ICRF44

Isotype: IgG1

Target: Integrin alpha M (CD11b; Mac-1a subunit). Recognises the human CD11b cell surface glycoprotein, a 165kD molecule also known as the α^M integrin, MAC-1 and CR3. This molecule is expressed as a heterodimer in association with the ß2 integrin, and is found on monocytes, granulocytes, NK cells and some peripheral blood lymphocytes. This antibody blocks some functions of CD11b.

Immunogen: Rheumatoid synovial cells and human monocytes.

Conjugate: Unconjugated

Myeloma used: Sp2/0-Ag14

Applications: FACS ; IHC-F ; IP ; WB

Recommended controls: Monocytes or neutrophils

Hybridoma culture conditions: DMEM +10%FCS (reduced to 5% once established, ~3 passages)

Contributor(s)

Inventor: Nancy Hogg
Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Properties

Format: Liquid

Concentration: 1 mg/ml

Unit size: 100 ug

Storage buffer: PBS with 0.02% azide

Storage conditions: 4° C for up to 1 month or -20° C long term

Shipping conditions: Dry ice

Purification: Affinity chromatography

Purity: Greater than 90%, as determined by SDS-PAGE

Directions for use: The applications listed for this monoclonal antibody are derived from information supplied by the originating laboratory and/or relevant published literature. These applications have not been independently validated by CancerTools.org. End users are responsible for performing appropriate titration and optimization for their experimental system. Application-specific guidelines will be provided when available.

References

- Serr et al. 2016. Nat Commun. 7:10991. PMID: 26975663.
- Wong et al. 2016. Sci Rep. 6:21023. PMID: 26876805.
- Bock et al. 2016. Pharmacol Res. :. PMID: 26794428.
- Chen et al. 2016. J Immunol. :. PMID: 26764035.
- Jobe et al. 2015. J Leukoc Biol. :. PMID: 26667473.
- Tosh et al. 2015. J Immunol. :. PMID: 26597011.
- Sugimoto et al. 2015. J Immunol. 195(4):1774-81. PMID: 26179903.
- Riise et al. 2015. J Immunol. 195(3):1121-8. PMID: 26085684.
- Tarique et al. 2015. Am J Respir Cell Mol Biol. :. PMID: 25870903.
- Mohanty et al. 2015. J Infect Dis. 211(7):1174-84. PMID: 25367297.
- Hong et al. 2015. Nat Commun. 6:6588. PMID: 25807344.
- Thurlow et al. 2010. Infect Immun. 78(11):4936-43. PMID: 20713628.
- Stapulionis et al. 2008. J Immunol. 180(6):3946-56. PMID: 18322203.
- Malhotra et al. 1986. Eur J Immunol. 16(9):1117-23. PMID: 3530784.

Material Citation

If use of this material results in a scientific publication, please cite the material in the following manner: Anti-CD11b (Integrin aM) [ICRF44], was invented by Nancy Hogg at Cancer Research UK, London Research Institute (CancerTools.org, 151052).